Deutsche Bank AG Grows Position in Moderna, Inc. (NASDAQ:MRNA)

Deutsche Bank AG grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 54.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,894,075 shares of the company’s stock after buying an additional 669,614 shares during the quarter. Deutsche Bank AG’s holdings in Moderna were worth $78,756,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. abrdn plc grew its stake in shares of Moderna by 28.1% during the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after acquiring an additional 69,360 shares during the period. Spire Wealth Management lifted its holdings in Moderna by 2,150.4% during the fourth quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock valued at $966,000 after purchasing an additional 22,192 shares in the last quarter. Proficio Capital Partners LLC raised its position in shares of Moderna by 4,418.9% during the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company’s stock valued at $6,127,000 after purchasing an additional 144,099 shares during the period. South Dakota Investment Council boosted its holdings in Moderna by 4.0% in the 4th quarter. South Dakota Investment Council now owns 299,399 shares of the company’s stock worth $12,449,000 after buying an additional 11,500 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company’s stock worth $300,219,000 after buying an additional 171,774 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. William Blair reissued a “market perform” rating on shares of Moderna in a report on Thursday, April 17th. Morgan Stanley cut their target price on Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. Evercore ISI lowered their price target on Moderna from $50.00 to $32.00 and set an “in-line” rating on the stock in a report on Friday, May 2nd. Barclays dropped their price target on Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a research note on Friday, May 2nd. Finally, Leerink Partners reduced their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $53.95.

Moderna Trading Down 0.5%

Shares of NASDAQ MRNA opened at $24.25 on Monday. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $170.47. The firm’s 50-day moving average price is $28.89 and its 200-day moving average price is $36.34. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of -2.61 and a beta of 1.99.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. The business had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company’s quarterly revenue was down 35.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.07) earnings per share. On average, equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.